| (Values in U.S. Thousands) | Sep, 2018 | Jun, 2018 | Mar, 2018 | Dec, 2017 | Sep, 2017 |
| Sales | 280 | 260 | 1,470 | 2,370 | 2,730 |
| Sales Growth | +7.69% | -82.31% | -37.97% | -13.19% | -64.45% |
| Net Income | -3,640 | -3,800 | -4,800 | -4,180 | -3,890 |
| Net Income Growth | +4.21% | +20.83% | -14.83% | -7.46% | -474.04% |
Aradigm Corp (ARDM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.